Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study

Leukemia Research

Volumn 37, Issue 8, 2013, Pages 911-916

  Mesa, Ruben A ^a   Shields, Alan ^b   Hare, Thomas ^c   Erickson Viitanen, Susan ^c   Sun, William ^c   Sarlis, Nicholas J ^c   Sandor, Victor ^c   Levy, Richard S ^c   Verstovsek, Srdan ^d  

^a MAYO CLINIC   (United States)

^b ADELPHI REAL WORLD   (United Kingdom)

^c Experimental Station   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Fatigue; Myelofibrosis; Patient reported outcomes; Quality of life; Ruxolitinib; Splenomegaly

Indexed keywords

JANUS KINASE 1; JANUS KINASE 2; PLACEBO; RUXOLITINIB;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE CORE 30 SCORE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INTERMEDIATE RISK PATIENT; MAJOR CLINICAL STUDY; MODIFIED MYELOFIBROSIS SYMPTOM ASSESSMENT FORM V2.0 TOTAL SYMPTOM SCORE; MYELOFIBROSIS; OUTCOME ASSESSMENT; PATIENT; PATIENT ASSESSMENT; PATIENT GLOBAL IMPRESSION OF CHANGE QUESTIONNAIRE; PATIENT REPORTED OUTCOME; PATIENT REPORTED OUTCOME MEASUREMENT INFORMATION SYSTEM FATIGUE SCORE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPLEEN SIZE; SYMPTOM; THERAPY DELAY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; JANUS KINASES; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBOS; PRIMARY MYELOFIBROSIS; PYRAZOLES; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPLEEN; TIME FACTORS;

EID: 84879781319     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.04.017     Document Type: Article

References (34)

1. Hasselbalch H.C. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?. Leuk Res 2009, 33:11-18.
2. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000, 342:1255-1265.
3. Mesa R.A., Niblack J., Wadleigh M., Verstovsek S., Camoriano J., Barnes S., et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007, 109:68-76.
4. Ostojic A., Vrhovac R., Verstovsek S. Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ther Clin Risk Manag 2012, 8:95-103.
5. Kralovics R., Passamonti F., Buser A.S., Teo S.-S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
6. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010, 24:1128-1138.
7. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
8. Delhommeau F., Jeziorowska D., Marzac C., Casadevall N. Molecular aspects of myeloproliferative neoplasms. Int J Hematol 2010, 91:165-173.
9. Quintás-Cardama A., Vaddi K., Liu P., Manshouri T., Li J., Scherle P.A., et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010, 115:3109-3117.
10. Vainchenker W., Dusa A., Constantinescu S.N. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 2008, 19:385-393.
11. Wang J.C., Chang T.H., Goldberg A., Novetsky A.D., Lichter S., Lipton J. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. Exp Hematol 2006, 34:1617-1623.
12. Schmitt A., Jouault H., Guichard J., Wendling F., Drouin A., Cramer E.M. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood 2000, 96:1342-1347.
13. Panteli K.E., Hatzimichael E.C., Bouranta P.K., Katsaraki A., Seferiadis K., Stebbing J., et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005, 130:709-715.
14. Cervantes F., Dupriez B., Pereira A., Passamonti F., Reilly J.T., Morra E., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113:2895-2901.
15. Scherber R., Dueck A.C., Johansson P., Barbui T., Barosi G., Vannucchi A.M., et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011, 118:401-408.
16. Mesa R.A., Schwager S., Radia D., Cheville A., Hussein K., Niblack J., et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009, 33:1199-1203.
17. Mesa R.A., Kantarjian H., Tefferi A., Dueck A., Levy R., Vaddi K., et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer 2011, 117:4869-4877.
18. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366:799-807.
19. Harrison C., Kiladjian J.J., Al-Ali H.K., Gisslinger H., Waltzman R., Stalbovskaya V., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012, 366:787-798.
20. Mesa R.A., Gotlib J., Gupta V., Catalano J.V., Deininger M.W., Shields A.L., et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2013, 31:1285-1292.
21. Tefferi A., Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008, 22:14-22.
22. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
23. Garcia S.F., Cella D., Clauser S.B., Flynn K.E., Lad T., Lai J.S., et al. Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol 2007, 25:5106-5112.
24. Farrar J.T., Young J.P.Jr., LaMoreaux L., Werth J.L., Poole R.M. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001, 94:149-158.
25. Messerer D., Engel J., Hasford J., Schaich M., Ehninger G., Sauerland C., et al. Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. Haematologica 2008, 93:826-833.
26. Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, et al; EORTC Quality of Life Group. EORTC QLQ-C30 reference values. Brussels, Belgium: EORTC, ; 2008. http://groups.eortc.be/qol/sites/default/files/img/newsletter/reference_values_manual2008.pdf.
27. Maringwa J.T., Quinten C., King M., Ringash J., Osoba D., Coens C., et al. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Support Care Cancer 2011, 19:1753-1760.
28. Maringwa J., Quinten C., King M., Ringash J., Osoba D., Coens C., et al. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann Oncol 2011, 22:2107-2112.
29. Sarlis N.J., Kaye J.A., Mitra D., Brown J.S., Piecoro L.T., Reith K., et al. Clinical features and symptoms of 180 patients with myelofibrosis and the burden of splenomegaly: a retrospective"real-world" assessment in the United States [abstract PP13]. J Oncol Pharm Pract 2012, 118:11.
30. Ahlberg K., Ekman T., Gaston-Johansson F., Mock V. Assessment and management of cancer-related fatigue in adults. Lancet 2003, 362:640-650.
31. Knobel H., Loge J.H., Brenne E., Fayers P., Hjermstad M.J., Kaasa S. The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors. Palliat Med 2003, 17:664-672.
32. Stone P., Hardy J., Huddart R., A'Hern R., Richards M. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000, 36:1134-1141.
33. Rollison D.E., Howlader N., Smith M.T., Strom S.S., Merritt W.D., Ries L.A., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112:45-52.
34. Vannucchi A.M. Management of myelofibrosis. Hematol Am Soc Hematol Educ Program 2011, 2011:222-230.